(Reuters) - Canada's Valeant Pharmaceuticals International Inc said its sweetened offer for drugmaker Allergan Inc would not be an all-cash bid as was expected.
Valeant, which plans to announce its improved offer on May 28, had launched a $47 billion unsolicited bid on April 22, along with activist investor William Ackman.
Valeant's current offer is worth $48.30 per share in cash and 0.83 of its share for each ALLERGAN (AGN.NY)share.
(Reporting by Esha Dey in Bangalore; Editing by Savio D'Souza)
Relacionados
- Allergan rechaza la oferta de compra de más de 33.000 millones presentada por Valeant
- Economía/Empresas.- Allergan rechaza la oferta de compra de más de 33.000 millones presentada por Valeant
- Valeant formaliza su OPA sobre Allergan, propietario de 'Botox'
- Valeant formaliza su OPA sobre Allergan, propietario de Botox
- Economía/Empresas.- Valeant formaliza su OPA sobre Allergan, propietario de Botox